Építés alatt – nem éles oldal
Belépés
LeállítvaFázis nélkül

Study Evaluating MyoRegulator® Treatment in Post-Stroke Upper Limb Spasticity

A legfontosabb adatok

Ki végzi
PathMaker Neurosystems Inc.
Hol
Cambridge és Charlestown (Egyesült Államok)Mind a 2 helyszín megnézése
Azonosító
Állapot
Leállítva
Résztvevők
28 fő vett részt
Kezdés
2022. márc. 4.
Befejezés
2024. jún. 30.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport színlelt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • MyoRegulator® device
A regiszteradat frissítve
2024. augusztus 15.
Miért állt le
Slow enrollment

Ki vehet részt

Életkor
18 év – 85 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 19 feltétel megnézéseKevesebb

Ki vehet részt

  • ≥ 18 to < 85 years of age
  • First single focal unilateral hemisphere lesion with diagnosis verified by brain imaging (MRI or CT scans) that occurred at least 6 months prior to study enrollment
  • At least 6 weeks of stable UE spasticity symptoms (as confirmed by medical history) with a baseline Modified Ashworth Scale (MAS) score of 1+ to 3 (on the 0, 1, 1+, 2, 3, 4 scale), inclusive, in the wrist flexor muscles
  • Willing to forgo botulinum toxin, phenol or alcohol injections into the muscles of the limb targeted for the study treatment; intrathecal baclofen; digitalis, and morphine for the subject's duration in the study
  • Willing to forgo upper extremity physical and occupational therapy for the duration of the study (lower extremity PT and OT are allowed)
  • Willing to maintain current regiment for oral spasticity medication(s) and neurotransmitter medication(s) for the subject's duration in the study
  • Cognitive function sufficient to understand the experiments and follow instructions (per interview with appropriate clinician)

Ki nem vehet részt

  • Change in antispastic oral medication (baclofen, clonidine, benzodiazepine, dantrolene, gabapentin, tizanidine) in the 2 months prior to study enrollment
  • Use of digitalis, morphine, or intrathecal pump in the week prior to study enrollment
  • Prior botulinum toxin injection(s) into the muscles of the limb targeted for the study treatment within 12 weeks of study enrollment
  • Prior phenol or alcohol injections into the muscles of the limb targeted for the study treatment within 6 months of study enrollment
  • Prior surgery for spasticity in the target muscle group
  • Prior transcranial or trans-spinal direct current stimulation for any reason
  • Presence of potential tsDCS risk factors:; Damaged skin at the stimulation sites (i.e., skin with ingrown hairs, acne, razor nicks, wounds that have not healed, recent scar tissue, broken skin, etc.); Lack of sensory perception at the stimulation sites; Presence of an electrically, magnetically, or mechanically activated implant (including cardiac pacemaker) or any other electrically sensitive support system with the exception of loop recorders; Ferrous metal in the path of the current flow (jewelry must be removed during stimulation); Past history of epileptic seizures or unexplained spells of loss of consciousness during the previous 36 months
  • Previous participating in a study involving the application of tsDCS
  • Other neurological conditions involving CNS impairment, including Parkinson's Disease, Multiple Sclerosis, and Spinal Cord Injury
  • Any medical condition that would prevent the subject from being able to participate in the clinical outcome measures
  • Fixed contractures or profound muscle atrophy of the target spastic wrist to be treated
  • Pregnancy in women (as determined by pregnancy test in pre-menopausal women)

Helyszínek itt: Egyesült Államok

  • Spaulding Rehabilitation HospitalCambridge, Egyesült Államok
  • Spaulding Rehabilitation HospitalCharlestown, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is a multi-center, randomized, double-blind (patient and evaluator), sham-controlled study to be conducted in stroke patients with upper-extremity spasticity. The main objectives of this study are to evaluate the performance and safety of the MyoRegulator® device in active- versus sham-treated patients after 5 consecutive days of treatment. The MyoRegulator® device is a non-significant risk (NSR) investigational non-invasive neuromodulation device that uses multi-site direct current (multi-site DCS) stimulation for the treatment of muscle spasticity.

A vizsgálat 2 csoportja

  • Active StimulationA vizsgált kezelés

    Five consecutive days of 20 minutes active stimulation with MyoRegulator® device

    Kezelés: MyoRegulator® device

  • Sham StimulationSzínlelt kezelés, összehasonlításként

    Five consecutive days of 20 minutes sham stimulation with MyoRegulator® device

    Kezelés: MyoRegulator® device

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Multi-Center, Randomized, Sham-Controlled Study Evaluating MyoRegulator® Treatment in Post-Stroke Upper Limb Spasticity
A regiszteradat frissítve
2024. augusztus 15.